A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) Remigromig (EYE103) in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD) (AMARONE)
A 2-part Study Consisting of an Open-label Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Single-masked Comparative Safety and Preliminary Efficacy Study of Intravitreal (IVT) Remigromig in a Mixed Population of Participants With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig (EYE103) in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of remigromig in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF.
In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of remigromig will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study.
In the second part of the study, called the dose finding part two doses of remigromig will be selected and their effectiveness will be compared. Approximately 80 participants will be entered in this part of the study.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Caba, Argentina, 1023
- Caba, Argentina
-
-
Buenos Aires
-
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1121ABB
- Ciudad Autonoma Buenos Aires
-
-
-
-
PR
-
Arecibo, PR, Puerto Rico, 00612
- Arecibo, PR
-
-
-
-
-
London, United Kingdom, W1G7LB
- London, UK
-
-
England
-
London, England, United Kingdom, NW10 7NS
- London, England
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Phoenix, AZ
-
-
California
-
Bakersfield, California, United States, 93309
- Bakersfield, CA
-
Modesto, California, United States, 95356
- Modesto, CA
-
Mountain View, California, United States, 94040
- Mountain View, CA
-
Sacramento, California, United States, 95825
- Sacramento, CA
-
Sacramento, California, United States, 95841
- Sacramento, CA
-
-
Colorado
-
Colorado Springs, Colorado, United States, 80909
- Colorado Springs, Colorado
-
Lakewood, Colorado, United States, 80288
- Lakewood, CO
-
-
Florida
-
Pompano Beach, Florida, United States, 33064
- Pompano Beach
-
-
Illinois
-
Lemont, Illinois, United States, 60439
- Lemont, NV
-
-
Maryland
-
Hagerstown, Maryland, United States, 21740
- Hagerstown, MD
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Reno, NV
-
-
South Carolina
-
West Columbia, South Carolina, United States, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Germantown, TN
-
Knoxville, Tennessee, United States, 37922
- Knoxville, TN
-
Nashville, Tennessee, United States, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, United States, 79606
- Abilene, TX
-
Amarillo, Texas, United States, 79109
- Amarillo, TX
-
Austin, Texas, United States, 78705
- Austin, TX
-
Bellaire, Texas, United States, 77401
- Bellaire, TX
-
Dallas, Texas, United States, 75231
- Dallas, TX
-
Katy, Texas, United States, 77494
- Katy, TX
-
McAllen, Texas, United States, 78503
- McAllen, TX
-
Plano, Texas, United States, 75075
- Plano, TX
-
Round Rock, Texas, United States, 78681
- Round Rock, TX
-
San Antonio, Texas, United States, 78240
- San Antonio, TX
-
The Woodlands, Texas, United States, 77384
- The Woodlands, TX
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- DME patients must be ≥ 18 years of age, NVAMD patients must be ≥ 50 years of age
- Diagnosis of either DME or NVAMD. DME patients must be treatment naïve. NVAMD patients can be either treatment naïve or treatment experienced.
- DME patients must have vision loss in the study eye
- NVAMD patients can be either treatment-naïve or treatment experienced with vision loss in the study eye
Exclusion Criteria:
- Be pregnant or breastfeeding
- History of cataract surgery and/or minimally invasive glaucoma surgery (MIGS) within 3 months of Screening
- Yttrium-Aluminum Garnet (YAG) laser capsulotomy within 2 months of Screening
- Any other condition except for DME or NVAMD or that could affect interpretation of study assessments
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Dose 1
Part 1 MAD Portion Dose 1 - Low Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Dose 2
Part 1 MAD Portion Dose 2 - Low-Mid Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Dose 3
Part 1 MAD Portion Dose 3 - Mid-High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Dose 4
Part 1 MAD Portion Dose 4 - High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: DME Medium Dose
Part 2 Naïve DME monotherapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: DME High Dose
Part 2 Naïve DME monotherapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Naïve NVAMD Medium Dose
Part 2 Naïve NVAMD combination therapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Naïve NVAMD High Dose
Part 2 Naïve NVAMD combination therapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Experienced NVAMD Medium Dose
Part 2 Experienced NVAMD combination therapy Medium Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
|
Experimental: Experienced NVAMD High Dose
Part 2 Experienced NVAMD combination therapy High Dose |
Remigromig is a humanized antibody formulated for IVT administration
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
Time Frame: Up to approximately 12 weeks
|
Systemic DLTs are defined as a Grade III (severe), IV (life threatening) or V (death related to adverse event) toxicities as defined in the National Cancer Institute (NCI) Common Toxicity Criteria, or any significant severe toxicity deemed related to study drug by the principal investigator. Ocular DLTs are defined as: loss of 4 or more lines of visual acuity, clinically significant inflammation, increase of intra-ocular pressure (IOP) from baseline of > or =15 mmHg, accelerated formation of cataract, other severe ocular abnormalities not usually seen in subjects with the condition under study, or significant retinal or choroidal vascular abnormalities seen on fluorescein angiogram deemed related to study drug by the investigator. |
Up to approximately 12 weeks
|
|
Number of Participants Who Experienced an Adverse Event (AE)
Time Frame: Up to approximately 12 weeks
|
An AE is any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. |
Up to approximately 12 weeks
|
|
Number of Participants Who Experienced a Serious Adverse Event (SAE)
Time Frame: Up to approximately 24 weeks
|
An SAE is defined as any adverse experience occurring at any dose that results in any of the following outcomes: Results in death; Is life threatening (immediate risk of death); results in persistent or significant disability/incapacity; requires participant hospitalization or prolongs participant hospitalization; or results in a congenital anomaly/birth defect in a neonate/infant |
Up to approximately 24 weeks
|
|
Number of Participants Who Experienced Clinically Meaningful Changes in Laboratory Assessments
Time Frame: Baseline and Week 12
|
Clinical laboratory tests, including overnight fasting serum chemistry, lipid panel, hematology, and coagulation panel were collected at baseline and at week 12 study visit. Any laboratory test result considered by the investigator to be clinically significant was considered to be an AE. Clinically significant abnormal values were followed up until repeat test results return to normal, stabilize, or are no longer clinically significant. |
Baseline and Week 12
|
|
Mean Change From Baseline in Best-Corrected Visual Acuity (BCVA) to Week 12 in the Study Eye - DME Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented. |
Baseline and Week 12
|
|
Mean Change From Baseline in BCVA to Week 12 in the Study Eye -NVAMD Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 12 is presented. |
Baseline and Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With ETDRS BCVA Response- Treatment-Naive DME Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Number of Participants With ETDRS BCVA Response- Treatment-Naive NVAMD Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who gained 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Mean Change in Retinal Central Subfield Thickness (CST) From Baseline in the Study Eye on Spectral Domain Optical Coherence Tomography (SDOCT): Treatment-naive DME Participants
Time Frame: Baseline and 12 weeks
|
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented. |
Baseline and 12 weeks
|
|
Mean Change in Retinal CST From Baseline in the Study Eye on SDOCT: Treatment-naive NVAMD Participants
Time Frame: Baseline and 12 weeks
|
SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. A negative change (decrease) in retinal CST from baseline indicates a decrease in retinal thickness or swelling and is considered a better outcome than no change or an increase in CST. The mean change at 12 weeks in the study eye for retinal CST from baseline is presented. |
Baseline and 12 weeks
|
|
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive DME Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Number of Participants With Loss of Vision From Baseline by 15 or More Letters at Week 12-Treatment Naive NVAMD Participants
Time Frame: Baseline and Week 12
|
Participants' BCVA in the study eye is measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The number of participants who lost 15 or more letters as measured by ETDRS from baseline in the study eye is presented. |
Baseline and Week 12
|
|
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive DME Participants
Time Frame: Baseline and Week 12
|
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening). |
Baseline and Week 12
|
|
Percent Change in Excess Retinal Fluid From Baseline at Week 12: Treatment-naive NVAMD Participants
Time Frame: Baseline and Week 12
|
Retinal fluid in the study eye was measured by central subfield thickness (CST) as evaluated on SDOCT. SDOCT machines and technicians were certified at each study site by the independent reading center (IRC) prior to study start. Images were sent to the IRC for assessment. This outcome measure evaluates the relative change in excess CST above > 300 um from baseline to Week 12, expressed as a percentage of the baseline value. The percent change from baseline in CST in the study eye is calculated as follows: (Excess CST Baseline-Excess CST Week 12/Excess CST Baseline) *100. Positive values represent a percent reduction in excess retinal fluid (clinical improvement), and negative values represent a percent increase in excess retinal fluid (clinical worsening). |
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EYE103-101
- MK-3000-003 (Other Identifier: Merck)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.